Drug Approval | February 03, 2022
USFDA approves first generic of Restasis
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Restasis has been approved for use in the U.S. for nearly 20 years, but until today, there was no approved generic product of this drug
Allocation for the healthcare sector has gone up but is still woefully short of expectations. A few leading voices from the hospital and consulting sectors share their perspective on what they expect from Budget 2022
_256_384.jpg)
The oversubscribed round was led by New York-based HOF Capital and welcomed new investors including Headline, East Ventures, MS&AD Ventures, DG Daiwa Ventures, Pioneer Fund, as well as existing investor Insignia Ventures Partners
Urges them to focus on tele-consultation like eSanjeevani and efficient monitoring of those in home isolation
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Occupancy is expected to be in the range of 60-62% while Average Revenue Per Occupied Bed (ARPOB) is expected to expand by least 6% in FY2022
KardiaMobile is the first personal ECG to be recommended by NICE for use within the National Health Service (NHS) in England and Wales
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Subscribe To Our Newsletter & Stay Updated
